These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 20631352)

  • 1. A role of the bile salt receptor FXR in atherosclerosis.
    Hageman J; Herrema H; Groen AK; Kuipers F
    Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1519-28. PubMed ID: 20631352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of bile acids and bile acid receptors in metabolic regulation.
    Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
    Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
    Fiorucci S; Mencarelli A; Palladino G; Cipriani S
    Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation.
    Watanabe M; Houten SM; Mataki C; Christoffolete MA; Kim BW; Sato H; Messaddeq N; Harney JW; Ezaki O; Kodama T; Schoonjans K; Bianco AC; Auwerx J
    Nature; 2006 Jan; 439(7075):484-9. PubMed ID: 16400329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acid-activated receptors in the treatment of dyslipidemia and related disorders.
    Fiorucci S; Cipriani S; Baldelli F; Mencarelli A
    Prog Lipid Res; 2010 Apr; 49(2):171-85. PubMed ID: 19932133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile acids and signal transduction: role in glucose homeostasis.
    Nguyen A; Bouscarel B
    Cell Signal; 2008 Dec; 20(12):2180-97. PubMed ID: 18634871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear bile acid receptor FXR as pharmacological target: are we there yet?
    Modica S; Moschetta A
    FEBS Lett; 2006 Oct; 580(23):5492-9. PubMed ID: 16904670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bile salts in liver regeneration.
    van de Laarschot LF; Jansen PL; Schaap FG; Olde Damink SW
    Hepatol Int; 2016 Sep; 10(5):733-40. PubMed ID: 27048617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Claudel T; Staels B; Kuipers F
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2020-30. PubMed ID: 16037564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FXR an emerging therapeutic target for the treatment of atherosclerosis.
    Mencarelli A; Fiorucci S
    J Cell Mol Med; 2010 Jan; 14(1-2):79-92. PubMed ID: 20041971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual activation of the bile acid nuclear receptor FXR and G-protein-coupled receptor TGR5 protects mice against atherosclerosis.
    Miyazaki-Anzai S; Masuda M; Levi M; Keenan AL; Miyazaki M
    PLoS One; 2014; 9(9):e108270. PubMed ID: 25237811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear receptors in cholesterol catabolism: molecular biology of the enterohepatic circulation of bile salts and its role in cholesterol homeostasis.
    Redinger RN
    J Lab Clin Med; 2003 Jul; 142(1):7-20. PubMed ID: 12878981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
    Kuipers F; Stroeve JH; Caron S; Staels B
    Curr Opin Lipidol; 2007 Jun; 18(3):289-97. PubMed ID: 17495603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acids as regulators of hepatic lipid and glucose metabolism.
    Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
    Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesoid X receptor: from medicinal chemistry to clinical applications.
    Fiorucci S; Mencarelli A; Distrutti E; Zampella A
    Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
    Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
    Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice.
    Zhang Y; Wang X; Vales C; Lee FY; Lee H; Lusis AJ; Edwards PA
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2316-21. PubMed ID: 16825595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
    Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
    FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
    Erice O; Labiano I; Arbelaiz A; Santos-Laso A; Munoz-Garrido P; Jimenez-Agüero R; Olaizola P; Caro-Maldonado A; Martín-Martín N; Carracedo A; Lozano E; Marin JJ; O'Rourke CJ; Andersen JB; Llop J; Gómez-Vallejo V; Padro D; Martin A; Marzioni M; Adorini L; Trauner M; Bujanda L; Perugorria MJ; Banales JM
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1335-1344. PubMed ID: 28916388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.